Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine.

UNLABELLED Infection with Streptococcus pyogenes, commonly known as group A Streptococcus (GAS), is responsible for acute and postinfectious complications, including rheumatic fever and rheumatic heart disease (RHD). RHD is a global health burden, and Australia's indigenous population has one of the highest incidences of RHD worldwide. A potential peptide (J14) vaccine candidate has been previously identified from the C-terminal region of the M protein. However, such peptide-based vaccine development is hampered by a lack of carriers and adjuvants suitable for humans use. We have developed a fully synthetic peptide subunit vaccine candidate based on polyacrylate dendritic polymer. Intranasal administration of this nanoparticulate construct without additional adjuvant induced J14-specific IgG, which was also capable of in vitro opsonization of GAS, highlighting the potential of self-adjuvanting polyacrylate nanoparticle-based construct as a peptide vaccine delivery platform that may afford promising opportunities for treating systemic GAS infection. FROM THE CLINICAL EDITOR Polyacrylate dendrimers offer a unique approach to a nasally administered vaccine for addressing rheumatic heart disease. This paper describes the delivery of the J14 peptide, a C-terminal derivative of M-protein in group A Streptococcus.

[1]  M. Moser,et al.  Carrier-induced, hapten-specific suppression: a problem of antigen presentation? , 1998, Journal of immunology.

[2]  M. Batzloff,et al.  Moving forward: a mucosal vaccine against group A streptococcus , 2009, Expert review of vaccines.

[3]  M. Good,et al.  Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. , 1997, International immunology.

[4]  D. Jackson,et al.  Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. , 2006, The Journal of infectious diseases.

[5]  L. Guilherme,et al.  T cell response in rheumatic fever: crossreactivity between streptococcal M protein peptides and heart tissue proteins. , 2007, Current protein & peptide science.

[6]  Manisha Pandey,et al.  Mechanism of Protection Induced by Group A Streptococcus Vaccine Candidate J8-DT: Contribution of B and T-Cells Towards Protection , 2009, PloS one.

[7]  Michael J Monteiro,et al.  Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. , 2010, Angewandte Chemie.

[8]  D. Jackson,et al.  Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice. , 2002, Vaccine.

[9]  G. Varghese,et al.  Dynamics of anti-M antibody response in a mouse model following intranasal infection with group A Streptococcus M-18. , 2005, Journal of medical microbiology.

[10]  E. Dewil,et al.  Effect of various adjuvants on secondary immune response in chickens. , 1998, Veterinary immunology and immunopathology.

[11]  I. Toth,et al.  Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. , 2008, Journal of medicinal chemistry.

[12]  J. Carapetis,et al.  Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci , 1996, Immunology.

[13]  Michael J Monteiro,et al.  Synthesis of 3-miktoarm stars and 1st generation mikto dendritic copolymers by "living" radical polymerization and "click" chemistry. , 2006, Journal of the American Chemical Society.

[14]  C. Olive.  Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease. , 2007, Current opinion in molecular therapeutics.

[15]  C. Phornphutkul,et al.  Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. , 1994, International immunology.

[16]  R. Kumar,et al.  M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. , 2005, Research in microbiology.

[17]  J. Langley,et al.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Batzloff,et al.  Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. , 2007, Vaccine.

[19]  E. Querol,et al.  Pathogen Proteins Eliciting Antibodies Do Not Share Epitopes with Host Proteins: A Bioinformatics Approach , 2007, PloS one.

[20]  V. Fischetti,et al.  Induction of Autoimmune Valvular Heart Disease by Recombinant Streptococcal M Protein , 2001, Infection and Immunity.

[21]  D. Jackson,et al.  New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population , 2000, Nature Medicine.

[22]  M. Tirrell,et al.  Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists , 2010, Expert review of vaccines.

[23]  A. Nesburn,et al.  Lipopeptide vaccines--yesterday, today, and tomorrow. , 2002, The Lancet. Infectious diseases.

[24]  A. Toubert,et al.  How an autoimmune reaction triggered by molecular mimicry between streptococcal M protein and cardiac tissue proteins leads to heart lesions in rheumatic heart disease. , 2005, Journal of autoimmunity.

[25]  I. Toth,et al.  Towards the development of a broadly protective group a streptococcal vaccine based on the Lipid-Core Peptide system. , 2007, Current Medicinal Chemistry.

[26]  M. Davies,et al.  Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. , 2003, The Journal of infectious diseases.

[27]  I. Toth,et al.  Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response. , 2010, Current drug delivery.

[28]  C. Aspord,et al.  Nasal administration of CTB‐insulin induces active tolerance against autoimmune diabetes in non‐obese diabetic (NOD) mice , 2002, Clinical and experimental immunology.

[29]  M. McDonald,et al.  Acute rheumatic fever: a chink in the chain that links the heart to the throat? , 2004, The Lancet. Infectious diseases.

[30]  R. Fernandez-Botran,et al.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells , 1988, Nature.

[31]  R. Anders,et al.  Mapping a conserved conformational epitope from the M protein of group A streptococci. , 1996, Peptide research.

[32]  V. Kabanov.  From synthetic polyelectrolytes to polymer-subunit vaccines , 2004 .

[33]  L. Van Melderen,et al.  Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. , 2008, Vaccine.

[34]  F. Shann,et al.  Systematic review of rheumatic heart disease prevalence in children in developing countries: The role of environmental factors , 2002, Journal of paediatrics and child health.

[35]  C. Phornphutkul,et al.  Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci , 1994, The Lancet.

[36]  R. Hunter,et al.  Murine IgG isotype responses to the Plasmodium cynomolgi circumsporozoite peptide (NAGG)5. I. Effects of carrier, copolymer adjuvants, and lipopolysaccharide on isotype selection. , 1991, Journal of immunology.

[37]  C. Jenkin,et al.  Complement-fixing IgG1 constitutes a new subclass of mouse IgG , 1979, Nature.

[38]  P. Doherty,et al.  Mucosal HIV-1 Pox Virus Prime-Boost Immunization Induces High-Avidity CD8+ T Cells with Regime-Dependent Cytokine/Granzyme B Profiles1 , 2007, The Journal of Immunology.

[39]  J. Carapetis,et al.  Acute rheumatic fever and rheumatic heart disease in the Top End of Australia's Northern Territory , 1996, The Medical journal of Australia.

[40]  N. Andrews,et al.  Effect of Vaccination with Carrier Protein on Response to Meningococcal C Conjugate Vaccines and Value of Different Immunoassays as Predictors of Protection , 2002, Infection and Immunity.

[41]  Jeffrey A Hubbell,et al.  Evaluation of pH-dependent membrane-disruptive properties of poly(acrylic acid) derived polymers. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  M. Good,et al.  Protective and Nonprotective Epitopes from Amino Termini of M Proteins from Australian Aboriginal Isolates and Reference Strains of Group A Streptococci , 2000, Infection and Immunity.

[43]  J. Ravetch,et al.  Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.

[44]  L. Hilgers,et al.  Alkyl-polyacrylate esters are strong mucosal adjuvants. , 2000, Vaccine.

[45]  J. Carapetis,et al.  Group A streptococcus, pyoderma, and rheumatic fever , 1996, The Lancet.

[46]  J. Carapetis,et al.  Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection , 1999, Epidemiology and Infection.

[47]  M. Good,et al.  Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. , 1997, Vaccine.

[48]  S. Raman,et al.  Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. , 2006, Nanomedicine : nanotechnology, biology, and medicine.